It is a transformational time in cancer research. As we
have delved deeper into the complexity of cancer, we have
experienced an explosion in our understanding of the
individual factors both inside and outside a cell that cause
cancer initiation, development, and progression. This
knowledge is beginning to unveil a clearer picture of how
these factors work together and are influenced by each
person’s unique biological characteristics.
Thanks to the efforts of countless researchers, physician-scientists, patient advocates, and other representatives
from all sectors of the biomedical research community (see
sidebar on The Biomedical Research Community: Powering
Progress Together, p. 9), we are developing new methods
for preventing, detecting, diagnosing, and treating cancer.
More effective and less toxic interventions improve patient
quality of life and ultimately, save more lives from cancer.
Between Aug. 1, 2015 and July 31, 2016, the FDA approved
18 new medical products for use in oncology— 13 new
anticancer therapeutics, one new cancer screening test, one
new diagnostic test, two new diagnostic imaging agents,
and a new medical device. During this same period, the
FDA also approved new uses for 11 previously approved,
This progress would not have been possible without strong,
bipartisan leadership and federal support for the NIH, NCI,
and FDA and innovative programs, such as the Precision
Medicine Initative (PMI). As the National Cancer Moonshot
Initiative gets underway, it will be important that this
promising effort receives support and robust funding as
well (see sidebar on Building Blocks of Further Progress
PROGRESS AGAINST CAN
To accelerate the pace of progress against cancer, we must:
Develop and train
BUILDING BLOCKS OF FURTHER PROGRESS AGAINST CANCER
• Increasing federal support for biomedical research and cross-cutting research initiatives
is crucial for furthering progress against cancer.
• Regulatory science and policy play a key role in making continued progress against cancer.
• Federal support is needed to develop and train the biomedical research workforce of tomorrow.
• Precision prevention and early detection have the potential to reduce the burden of cancer.
In this section you will learn: